prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Prostate%20cancer Signs and Symptoms

Introduction

  • One of the most common cancers in men >50 years of age 

Signs and Symptoms

  • Weak urinary stream
  • Polyuria, nocturia
  • Hematuria
  • Erectile dysfunction
  • Pelvic pain, back pain, chest pain
  • Lower extremity weakness or numbness
  • Loss of bladder or bowel control

Risk Factors

  • Age (increased risk in men >50 years old)
  • Positive family history (1st-degree relatives and relatives diagnosed with prostate cancer at an early age doubles the risk)
  • Ethnicity (African-American, Caribbean men of African ancestry)
  • Chemical exposures (toxic combustion products)
  • Genetic mutations: Breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2) mutations, deoxyribonucleic acid (DNA) mismatch repair genes [MutS Homolog 2 (MSH2), MutL Homolog 1 (MLH1), Lynch syndrome], insulin-like growth factor-1 (IGF-1)
  • Other risk factors under research include a positive medical history of inflammation of the prostate gland [eg prostatitis, STDs, proliferative inflammatory atrophy (PIN)] and vasectomy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.